KRAS and cancer: Different combinations of drugs involved in downstream pathway inhibition, such as SOS and SHP2 inhibitors, are able to reduce adaptive escape mechanisms via MAPK in KRAS mutant or amplified cancer cells in gastric cancer cell lines in vitro and in vivo.